Zenith Drugs Management
Management criteria checks 2/4
Zenith Drugs' CEO is Sandeep Bhardwaj, appointed in Sep 2023, has a tenure of 1.25 years. directly owns 23.33% of the company’s shares, worth ₹333.40M. The average tenure of the management team and the board of directors is 1.3 years and 5.4 years respectively.
Key information
Sandeep Bhardwaj
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.3yrs |
| CEO ownership | 23.3% |
| Management average tenure | 1.3yrs |
| Board average tenure | 5.4yrs |
CEO
Sandeep Bhardwaj (46 yo)
1.3yrs
Tenure
₹4,800,000
Compensation
Mr. Sandeep Bhardwaj is Managing Director since September 16, 2023 and served as its Chief Financial Officer from September 16, 2023 to August 31, 2024 and Director since October 31, 2003 of Zenith Drugs L...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Director | 1.3yrs | ₹4.80m | 23.33% ₹ 333.4m | |
| Executive Director | 23.8yrs | ₹3.60m | 23.33% ₹ 333.4m | |
| Executive Director | 9.5yrs | ₹306.00k | 23.33% ₹ 333.4m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Company Secretary & Compliance Officer | 1.3yrs | no data | no data |
1.3yrs
Average Tenure
45.5yo
Average Age
Experienced Management: ZENITHDRUG's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Director | 21.2yrs | ₹4.80m | 23.33% ₹ 333.4m | |
| Executive Director | 23.8yrs | ₹3.60m | 23.33% ₹ 333.4m | |
| Executive Director | 9.5yrs | ₹306.00k | 23.33% ₹ 333.4m | |
| Non- Executive Director | 1.3yrs | no data | no data | |
| Independent Director | 1.3yrs | no data | no data | |
| Independent Director | 1.3yrs | no data | no data |
5.4yrs
Average Tenure
46yo
Average Age
Experienced Board: ZENITHDRUG's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 15:23 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zenith Drugs Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|